Health ❯ Neurology

Alzheimer's Disease

Cognitive Decline Risk Factors Symptoms Cognitive Function Biomarkers Genetic Risk Factors Research Studies Clinical Trials Genetic Factors Treatment Research Treatment Options Diagnosis Cognitive Resilience Treatment Approval Amyloid Plaque Genetic Causes Research on Alzheimer's Memory Processing Tau Tangles Dementia Cytokines Neurodegenerative Disorders Pathology Risk Reduction Down Syndrome Protein Markers Memory Impairments BACE1 Protein Causes Genetic Predisposition Brain Morphology Disease Modeling Sex Differences Gender Differences Parkinson's Disease Brain Aging Environmental Factors Vascular Health Early-Onset Alzheimer's Beta-Amyloids Drug Repurposing Cerebrospinal Fluid Glymphatic System Cognitive Impairment Occupational Health Amyloid Plaques Cytomegalovirus Drug Treatments Herpesviruses Posterior Cortical Atrophy Complications Early Detection

Alector Ends Latozinemab After Phase 3 Failure, Slashes Workforce

Failure to convert higher progranulin levels into slowed FTD progression is prompting a shift of resources to other trials.